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Objectives: This study aimed to explore the period between onset of
pain and hospital-admission (pain-to-admission time) in patients with
acute pancreatitis (AP), to investigate the prognostic value and associ-
ated factors of this time, and to ascertain the knowledge about the pan-
creas in these patients.
Methods: An analysis of a prospective multicenter study was done,
which included 188 patients with AP.
Results: Median pain-to-admission time was 27 hours (interquartile
range, 6.0Y72.0). Median pain-to-admission time was significantly
shorter in intensive care unit (ICU) patients (10 hours) compared to
non-ICU patients (36 hours) (P = 0.045). Short pain-to-admission time
was associated with high pain level. Median pain level (0, no pain; 10,
maximal pain) was 8.0 (interquartile range, 7.0Y10.0). Older age corre-
lated with lower pain level (r = j0.26; P = 0.002). Multiple logistic
regression analysis including the admission values for serum lipase
and C-reactive protein and the corresponding interactions to the pain-
to-admission time showed substantial discriminative ability regarding
ICU admission (concordance index, 0.706; P = 0.006). 86% (112/130)
knew that they have a pancreas, 72% (81/112) of these patients knew
that AP exists, and 56% (45/81) recognized that AP is potentially fatal.
Conclusions: Knowledge about AP in hospitalized AP patients is
poor. Serum lipase and C-reactive protein in dependency of the pain-
to-admission time might be a suitable predictor for severity of AP.
Key Words: prognostic value, C-reactive protein, serum lipase,
time to admission
(Pancreas 2013;42: 647Y654)
A cute pancreatitis (AP) is a severe and potential life-threatening disease with an incidence of 19.7 to 42.8/
100,000/y.1,2 Although approximately 85% of AP episodes are
mild and self-limiting, severe cases have a mortality of up to
42%.3,4 The diagnosis is based on typical clinical symptoms
and laboratory tests.5 Early diagnosis and immediate therapyV
elimination of the causing agent, intravenous fluid replacement,
and analgesicsVare of high importance in the management
of AP.5Y9 To be able to start therapy timely, the patient has to
recognize AP-induced pain, to appropriately estimate pain se-
verity, and to show up in the emergency department as soon as
possible. The pain-to-admission time might be shortened if the
patient has knowledge of the existence of the pancreas, where
the pancreas is located, that the pancreas can get inflamed, can
cause pain, and that this is a good reason to consult a physician.
The aim of this extended analysis of a previously published
prospective study on AP was to determine the period between
onset of pain and admission to the hospital (pain-to-admission
time) in patients experiencing AP and to determine the influ-
encing factors associated with the delay as well as the prog-
nostic value of this period. A further aim was to investigate the
knowledge about the pancreas and AP in hospitalized patients
experiencing AP.
MATERIALS AND METHODS
This is an extended analysis of data from a prospective
multicenter study by our group on the incidence of AP.2 Eval-
uation of the patients’ first symptoms, knowledge on AP, initial
management, and pain-to-admission time were a priori end
points of the prospective multicenter PROST (Pancreatitis
during Oktoberfest) study. This was a prospective study of
188 patients with AP, treated at 27 hospitals in the greater area
of Munich, Germany (2,970,000 inhabitants) during the 2008
Oktoberfest and showed that the incidence of AP does not rise
during the world’s largest beer fair compared with two 18-day
control periods but is higher than previously described in
Germany. All patients admitted to the hospital because of AP
were interviewed using a questionnaire. They were asked about
the onset of pain, about their own explanation of the symptoms,
and their personal measures against their complaints. The pain-
to-admission time was rounded to the nearest hour. Additionally,
patients were explored if they ever had heard about AP, and if
they thought AP was a dangerous disease. Pain level was mea-
sured on a scale from 0 (no pain) to 10 (maximal pain).
Statistical Analysis
Statistical analyses were performed using IBM SPSS Sta-
tistics software (version 19, SPSS Inc, Chicago, Ill). Descriptive
data are presented as median and interquartile range (IQR). In
case of missing values, proportions were calculated based on the
number of valid data. To compare quantitative data between 2
independent subgroups, Mann-Whitney U test was performed.
Spearman correlation coefficient (r) was calculated to assess
bivariate relationship of ordinal or continuous parameters. Pa-
rameters with a P G 0.1 in univariable analysis and a limited
number of factors with high probability of impact were con-
sidered for multivariable logistic regression analyses regarding
dichotomous end points. To assess the discriminative ability of
the resulting regression models, the concordance index (c-index =
area under the curve) was calculated based on the resulting
predicted probabilities by a receiver operating characteristics
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analysis. Piecewise log-linear models were used to assess rel-
ative impact of ordinal- or quantitative data on right-skewed
outcome variables as pain-to-admission time. All statistical tests




Patients’ characteristics are shown in Table 1. Of the 188
patients, 128 (68%) answered all questions about their knowl-
edge on the pancreas and AP.
Pain Level
In general, patients experienced severe pain. The median
pain level on a scale from 0 to 10 was 8.0 (IQR, 7.0Y10.0) on
hospital admission. Distribution of the pain levels is shown
in Figure 1. There was a weak but statistically significant inverse
correlation between age and pain level (r = j0.26; P = 0.002).
Pain-to-Admission Time
The median pain-to-admission time was 27 hours (range,
0Y672; IQR, 6.0Y72.0 hours). Despite marked pain, only 50%
of patients were admitted to the hospital within 24 hours after
onset of pain (Fig. 2). For pain levels greater or equal than 6, the
pain-to-admission time significantly decreased with increasing
pain level [decrease for each 1-U pain level, 27%; 95% confi-
dence interval (CI), 59%Y89%; P = 0.003] (see Fig. 1, Supple-
mental Digital Content 1, http://links.lww.com/MPA/A203).
Univariable comparison of the pain-to-admission time re-
vealed no significant differences between the categories of the
parameters sex (P = 0.407), etiology (alcoholic, P = 0.262;
biliary, P = 0.593), principal residence (city of Munich or sur-
rounding area, P = 0.618), and the knowledge that AP is a po-
tential fatal disease (P = 0.250).
Prognostic Factors on Hospital Presentation
C-Reactive Protein
Low values of C-reactive protein (CRP) on admission were
associated with short pain-to-admission time (r = +0.334; P G
0.001). Furthermore, low values of CRP on admission weakly
correlated with high pain intensity (r =j0.208; P = 0.021). The
median time from onset of pain to maximum value of CRP was
3 days (IQR, 2Y5 days; Fig. 3A). The highest maximum values
of CRP were also observed around day 3 after onset of pain
(Fig. 3B). The median of maximum CRP values was 13.9 mg/dL
(IQR, 3.3Y26.2 mg/dL).
Lipase
Whereas patients with early presentation had lower CRP
levels (see previously mentioned), short pain-to-admission time
correlated with higher serum values of lipase on admission
(r = j0.226; P = 0.019). In 38/110 (35%) patients, the highest
value of serum lipase was measured within the first day after on-
set of pain (Fig. 4A). The median time from onset of pain to
highest maximum values of lipase was 2 days (IQR, 0.4Y3.8 days;
Fig. 4B) with a median of maximum lipase values of 1211 U/L
(IQR 433Y2668 U/L). Serum lipase values on admission did not
considerably correlate with the pain level (r = +0.176; P = 0.083).
Prognostic Value of the Pain-to-Admission Time
in Association With CRP and Serum Lipase
The pain-to-admission time was significantly shorter in
intensive care unit (ICU) patients (10 hours) compared to non-
ICU patients (36 hours; P = 0.045).
TABLE 1. Patients Characteristics (n = 188)
Age, y 52.0 (41.0Y69.8)
Sex, male 121/188 (64.4)
Body height, cm 174 (168Y180)
Body weight, kg 78 (68Y89)
Body mass index, kg/m2 25.4 (22.9Y28.5)
Residence, in town 74/182 (40.7)
Biliary AP 65/188 (34.6)
Alcoholic AP 69/188 (36.7)
Time between onset of pain and hospital
admission, h
27.0 (6.0Y72.0)
Pain level, 1Y10 8.0 (7.0Y10.0)
Where applicable, data are presented as median with IQR (25thY75th
percentile); otherwise, number (%).
FIGURE 1. Bar plot showing the distribution of the pain levels 0
(no pain) to 10 (maximal pain).
FIGURE 2. Bar plot showing the distribution of patients admitted
to the hospital within categorized time intervals.
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There was an inappropriate discriminative performance of
the single parameters CRP (c-index, 0.50) and lipase (c-index,
0.64) for the prediction of ICU admission. However, because
relevant time dependencies were apparent in the descriptive
analysis, an additional impact of the pain-to-admission time
(c-index, 0.63) on the predictive performance of these markers
was hypothesized. Therefore, a multiple logistic regression anal-
ysis including the admission values for CRP and serum lipase
and the corresponding interactions to the pain-to-admission time
was performed. This interaction model showed a substantial
FIGURE 3. Bar plot showing the frequency of maximum levels of C-reactive protein since onset of pain (A). Scatter plot showing the
absolute maximum levels of C-reactive protein since onset of pain (B). Solid and partly dotted lines depict the smoothed moving average.
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discriminative ability regarding ICU admission (c-index, 0.706;
95% CI, 0.570Y0.841; P = 0.006; see Fig. 2, Supplemental
Digital Content 2, http://links.lww.com/MPA/A204). With re-
gard to practical applications, we developed a nomogram to
predict need for ICU admission based on the parameters CRP,
lipase, and pain-to-admission time (see Fig. 3, Supplemental
Digital Content 2, http://links.lww.com/MPA/A205).
Patients’ Suspected Diagnosis and Self-Therapy
The most frequent causes of pain suspected by the patients
were diseases of the stomach/bowel (52/127, 41%). Only 29/127
(23%) of the patients associated their complaints to any affection of
the pancreas. Of the 127 patients who answered this question, 9 (7%)
suspected an impairment of the liver, 21 (17%) suspected various
extraintestinal disorders, and 16 (13%) patients had ‘‘no idea’’ at all.
FIGURE 4. Bar plot showing the frequency of maximum levels of serum lipase since onset of pain (A). Scatter plot showing the absolute
maximum levels of serum lipase since onset of pain (B). Solid and partly dotted lines depict the smoothed moving average.
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Of the 137 patients, 72 (53%) did not start any therapy
on their own, 52 (38%) took some kind of drugs. Among these,
33 (24%) used pain reliever, 12 (9%) proton pump inhibitors,
8 (6%) used butylscopolamine, and 8 (6%) took other drugs
(multiple answers possible); 13 (10%) used nonpharmacological
therapies including tea drinking and hot-water bag.
Knowledge About the Pancreas and Pancreatitis
Of the 130 patients who answered the questions about their
knowledge on the pancreas and AP, 112 (86%) were aware that
they have a pancreas; of the 128 patients, 80 (63%) knew the
correct anatomic position and 69 (54%) also knew the right
physiological function of this organ. Regarding AP, 81/112
(72%) of the patients who knew that they have a pancreas were
aware of this disease and 45/81 (56%) of those patients recognized
that this is a potentially severe and fatal disease.
In univariate analysis, patients with a first-degree relative
experiencing a pancreatic disease knew significantly more often
that they have a pancreas compared to patients without pancre-
atic ill relatives [21/21 (100%) vs 88/106 (83%); P = 0.039].
Patients with diabetes mellitus significantly less often knew that
they have a pancreas than patients not experiencing diabetes
mellitus [15/21 (71%) vs 95/107 (89%); P = 0.043]. Etiology
of AP, age, sex, residency, and recurrent attack of AP showed
no substantial influence on the knowledge about the pancreas.
P values are taken from the adjusted multivariable logistic re-
gression model. In multivariable analysis including these pa-
rameters, only diabetes mellitus had a statistical significant
negative influence on the knowledge about the existence of the
pancreas (odds ratio, 0.254; 95% CI, 0.067Y0.967; P = 0.045).
Regarding the knowledge of the entity of AP, multivariable
logistic regression analysis including the parameters sex, age,
place of residence, alcoholic etiology, biliary etiology, recurrent
attack of AP, family history of pancreatic disease, and diabetes
mellitus showed only alcoholic etiology (odds ratio, 3.670; 95%
CI, 1.236Y10.900; P = 0.019) as an independent factor to know
that a disease ‘‘acute pancreatitis’’ exists.
DISCUSSION
This article provides data regarding pain-to-admission time
and patients’ knowledge on AP, taken from a prospective mul-
ticenter study by our group (PROST study).2
Early prediction of severity of AP is of high importance
for triage which patient has to be treated as an outpatient, in-
patient, or even ICU-patient. A lot of research has been done
on this subject and a lot of single parameters, for example, CRP,
procalcitonin, interleukin-6, D-dimer, and serum urea nitrogen
(SUN) have been suggested as predictors for disease sever-
ity.10Y14 Because single parameters are susceptible for failure
and no single parameter provides appropriate predictive capa-
bilities, many scores have been introduced, for example, Ranson
score, Balthazar CT severity index, Pancreatitis Outcome Pre-
diction (POP) score, bedside index for severity in AP (BISAP)
score, and harmless AP score (HAPS) to predict a severe or
harmless course of AP.4,15Y19 Furthermore, several mostly un-
known scores, including artificial neural networks, have been
developed.20Y24 However, there are different shortcomings with
all of them. Some parameters are not obtainable everywhere
or are expensive, some scores are complex, have either a low
negative predictive value (NPV) or low positive predictive
value (PPV), or predict outcome not earlier than 48 hours after
admission. Therefore, our study focused on early and widely
available predictors including simple anamnestic data, which
might be underrepresented in the current scores. According
to our data, short pain-to-admission time correlates with
higher probability of ICU treatment. Furthermore, short pain-
to-admission time is associated with high pain levels, low
values of CRP on admission, and high values of serum lipase
on admission. Andersson et al24 recently presented an artificial
neural network model for prediction of severity of AP, including
for the first time the duration of pain as one of the predicting
factors and showing shorter duration of pain until arrival at the
emergency department for severe cases. The primary analysis
of our data showed high serum lipase values on admission,
among others, as a predictor for ICU treatment.2 Whereas CRP
has shown to be a prognostic factor for severity of AP, the value
of lipase frequently is considered to have diagnostic rather than
predictive qualities.25Y27 CRP and serum lipase are dependent
on the duration of AP and show contrary courses: Serum lipase
increases 4 to 8 hours after onset of AP and reaches a maxi-
mum at approximately 24 hours, followed by a continuous de-
crease for 8 to 14 days. In contrast, CRP has a delayed increase
with a predictive value starting at approximately 36 hours and
a maximal value at 72 to 96 hours after onset of symptoms.10,25
According to these findings, serum lipase should have a high
PPVand NPV within the first approximately 24 hours, followed
by a high PPV but low NPV. In contrast, CRP has a low NPV
within the first roughly 72 hours, followed by a high NPV and
high PPV after approximately 96 hours. Therefore, a combina-
tion of CRP and lipase in dependency of the time since the onset
of pain might provide a useful prediction formula.10,28Y30 Our
data suggest that serum lipase and CRP on admission in de-
pendency of the time since onset of pain is a suitable predictor
for the need of ICU treatment. This underlines that predictive
capabilities of several markers markedly depend on the time
since onset of symptoms as previously postulated.30
We choose ICU admission as end point because it is well
defined and available for all patients, in contrast to the Atlanta
severity classification or complex scores like APACHE-II,
Ranson, or BISAP score.31,32 Furthermore, some patients might
not have developed severe AP according to the Atlanta classi-
fication due to the close monitoring and intensive treatment in
the ICU. Except for one patient, all patients who were trans-
ferred to the ICU had either severe AP according to the Atlanta
classification (17/40; 43%) or had at least 1 well-established
prognostic factor regarding severe AP on admission. These
prognostic factors included the following values: serum glucose
greater than 250 mg/dL in patients without diabetes mellitus
(12/40; 30%), hematocrit greater than 44% (14/40; 35%), and
SUN greater than 22 mg/dL on admission (23/40; 58%) or a rise
of SUN within 24 hours after admission (2/40; 5%).15,33Y35
The only exception mentioned previously was an 89-year-
old lady experiencing biliary AP with cardiac events in her
medical history. Therefore, all patients had a good indication
to be transferred to the ICU.
In a region with unrestricted and fast access to medical
service, pain-to-admission time might be mainly determined by
patients’ assessment of symptoms and severity of the causes
supposed. Therefore, the questionnaire investigated patients’
suspected etiology of complaints and their knowledge about the
pancreas and AP. Several studies demonstrated that in patients
with acute coronary syndrome or stroke educational campaigns
resulting in better patients’ awareness for early symptoms can
shorten the time between appearance of first symptoms and
hospital admission.36Y38 Furthermore, shortened time between
onset of symptoms and beginning treatment has been shown to
improve outcome in these patients.39,40 Although cardiovascu-
lar diseases are much more frequent and have a higher mor-
tality, earlier beginning of treatment in patients experiencing
AP could also improve outcome in these patients. Similar to
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cardiovascular diseases, there isVdespite a lack of supporting
dataVuniversal agreement that aggressive and early treatment
(ie, fluid resuscitation) is critical in the therapy for AP.41 Be-
cause there are no data on knowledge and awareness of early
symptoms in AP, we also investigated the knowledge about
the existence, anatomy, and function of the pancreas as well as
early symptoms of AP. Although 86% of patients with AP knew
that they have a pancreas, only 72% of these patients knew that
the pancreas can get inflamed and only 56% recognized that this
is a potential fatal disease. This implicates that the knowledge
on the pancreas and pancreatitis is poor.
The median pain-to-admission time was 27 hours. Because
early fluid resuscitation is one of the most important parts of
therapy for AP, an admission to the hospital and initiation of
fluid administration as soon as possible is desirable.6Y8 A study
by Brown et al34 showed a hematocrit level greater than or equal
to 44% on admission and failure of admission hematocrit to
decrease at 24 hours after admission were the best predictors of
necrotizing pancreatitis, also indicating the value of early ther-
apy. Furthermore, the mostly used and most useful severity
scores are calculated within the first 48 hours and patients with
AP who already had an organ failure at first presentation
had a significant higher mortality.42Y44 Therefore, the pain-
to-admission time should be shortened. Especially patients with
increased risks to develop AP, for example, problem drinkers
and patients with cholecystolithiasis should know about their
pancreas and pancreatitis. Only patients admitted because of
alcohol-induced AP, but not patients with biliary AP, knew more
often that pancreatitis exists compared to patients with AP due
to other reasons. This suggests that physicians fail to inform
patients at the diagnosis of cholecystolithiasis about the risk
of biliary AP. Assuming a prevalence of cholecystolithiasis of
20% and an incidence of biliary pancreatitis of 14.8/100,000/y
in Germany, the risk of patients with cholecystolithiasis to de-
velop an episode of biliary pancreatitis is 0.08% per year, that is,
1 of 1333 per year.2,45Y47 We realize that this is a low number,
however, considering rising life expectancy, the lifetime risk is
much higher. Furthermore, biliary pancreatitis might be fatal for
the individual patient and the medical education is very simple.
Against our expectations, the knowledge on the pancreas in
patients with diabetes mellitus was worse compared to patients
without diabetes. This might be because patients experiencing
diabetes focus on the endocrine function of the pancreas.
As the elimination of the causing agent is the only casual
therapy for AP and a high percentage of AP is caused by immod-
erate alcohol intake, Takeyama48 observed the drinking habits of
patients after the first attack of AP. They found a higher risk of
recurrence, progression to chronic pancreatitis, and development
of diabetes in patients who maintained their drinking level com-
pared to patients who discontinued or reduced alcohol consump-
tion. Also, another study supports these findings.49 In our study,
90.0% of patients with alcohol-induced AP previously had re-
ceived admonitions to reduce immoderate alcohol consumption.
The efforts to improve patients’ outcome are not only based
on medical but also on economic reasons. Two recent US studies
calculated the annual direct medical costs in the United States
to $2.2 billion for AP and $3.7 billion for AP and chronic pan-
creatitis.50,51 Therefore, the awareness of the pancreas, of pan-
creatitis, and of the impact of alcohol consumption and smoking
on the risk of acute and chronic pancreatitis must be raised in
our population, especially in patients with risk factors also in-
cluding cholecystolithiasis.52
Summing up, AP is a not infrequent, potential fatal and
expensive disease. The first hours of the disease seem to be the
most susceptible time for effective therapy. With a median
pain-to-admission time of 27 hours, the first important day is
lost by the patient himself. Educational efforts on patients’
awareness could shorten the pain-to-admission time and
therefore gain valuable time for the therapy for AP. Especially
people on risk, for example, patients with cholecystolithiasis
and/or immoderate alcohol consumption, should be educated
regarding AP.
There are some limitations of this study. Despite the mul-
ticenter approach of the study, it was conducted in a limited
area, the observation period was only 54 days, and only 188
patients were included. We do not know the exact reasons for
ICU admissions of the individual patients but all except one had
a severe AP according to the Atlanta classification or at least
one prognostic factor regarding a severe course. However, con-
clusions regarding the prognostic capability of the admission
values for serum lipase and CRP and the corresponding inter-
actions to the pain-to-admission time have to be confirmed in
larger and interventional studies and different populations.
We conclude that the knowledge about AP in hospital-
ized AP patients is poor with an inappropriately long pain-
to-admission time. To improve the outcome of patients
with AP by starting therapy as early as possible, the pain-to-
admission time should be shortened and the knowledge about
AP should be improved, especially in patients at risk. Serum lipase
and CRP have appropriate predictive value regarding severity of
AP only when used in the context of the time since onset of pain.
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Klinikum München Pasing: Dr D. Bergemann and
Dr F. Neumann.
Klinik München Perlach: Dr M. Bergholtz and Dr F. Martin.
Klinikum rechts der Isar der Technischen Universität München:
Sharon Page.
Klinikum Rosenheim: Dr J. Boedecker and Dr H. Huff.
Rotkreuzklinikum München: Dr E. Ahrens, Prof Dr P. Born, and
Dr S. Petersen.
Privatklinik Dr Robert Schindlbeck: Dr M. Brennenstuhl and
Dr U. Middeler.
Phillip et al Pancreas & Volume 42, Number 4, May 2013
652 www.pancreasjournal.com * 2013 Lippincott Williams & Wilkins
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Klinikum Schwabing: Dr H. J. Fischer, Dr E. Höcherl, and
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